Company: BIAF
Filing Date: 2025-10-09
Form Type: 424B5
Source: 0001493152-25-017591
Chunk: 2

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-10-09
Form: 424B5
Chunk 2
---
 Description of Capital Stock                      |   35 |
| Description of Debt Securities                    |   39 |
| Description of Warrants                           |   43 |
| Description of Units                              |   45 |
| Legal Ownership of Securities                     |   45 |
| Plan of Distribution                              |   48 |
| Legal Matters                                     |   49 |
| Experts                                           |   49 |
| Where You Can Find More Information               |   49 |
| Incorporation of Certain Information by Reference |   50 |

No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus supplement or the accompanying prospectus. You must not rely on any unauthorized information or representations. This prospectus supplement and the accompanying prospectus are an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus supplement and the accompanying prospectus is current only as of their respective dates.

| S-i |

<div align='center'>ABOUT THIS PROSPECTUS SUPPLEMENT</div>

On November 16, 2023, we filed with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-3 (File No. 333-275608) utilizing a shelf registration process relating to the securities described in this prospectus supplement, which registration statement was declared effective on November 27, 2023. Under this shelf registration process, we may, from time to time, sell up to $25 million in the aggregate of shares of common stock, shares of preferred stock, debt securities, warrants, and units.

This document consists of two parts. The first part is the prospectus supplement, including the documents incorporated by reference herein, which describes the specific terms of this offering. The second part, the accompanying prospectus, including the documents incorporated by reference therein, provides more general information. In general, when we refer only to the prospectus, we are referring to both parts of this document combined. Before you invest, you should carefully read this prospectus supplement, the accompanying prospectus, all information incorporated by reference herein and therein, as well as the additional information described under the heading “Where You Can Find More Information.” These documents contain information you should carefully consider when deciding whether to invest in our securities.

This prospectus supplement may add, update or change information contained in the accompanying prospectus. To the extent there is a conflict between the information contained in this prospectus supplement